TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05733351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV
Study: NCT06596434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: 4-Aminopyridine
Description: Active study drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06596707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconomer
Description: zirconia modified glass ionomer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid composite
Description: conventional composite
Study: NCT06586983

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg po OD

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg po OD

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg po OD
Study: NCT06600945

Intervention type: OTHER
Intervention: Cataract surgery
Description: With local anesthetic in peribulbar anesthesia

Intervention type: OTHER
Intervention: Cataract surgery
Description: With local anesthetic in peribulbar anesthesia

Intervention type: OTHER
Intervention: Cataract surgery
Description: With local anesthetic in peribulbar anesthesia
Study: NCT06594432

Intervention type: DRUG
Group type: OTHER
Intervention: R-CHOP+Z+MTX
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: R-CHOP+MTX
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Study: NCT06603896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy and placebo patches will be used

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy and placebo patches will be used

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy and placebo patches will be used
Study: NCT06543199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local application of hyaluronic acid agent to the wound site
Description: Evaluation of the effect of local use of hyaluronic acid agent on wound healing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local application of hypericum perforatum L to the wound site
Description: Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound healing monitoring
Description: Doctor visit on days 3, 7, 14, 21 and 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound healing monitoring
Description: Doctor visit on days 3, 7, 14, 21 and 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound healing monitoring
Description: Doctor visit on days 3, 7, 14, 21 and 28
Study: NCT06590298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
Description: The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
Study: NCT06592599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Description: Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation.
Study: NCT06601049

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ResArgin
Description: Resveratrol-based supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ResArgin
Description: Resveratrol-based supplement
Study: NCT06325813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive TMS
Description: In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive TMS
Description: In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
Study: NCT05650736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
Study: NCT05526066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT05286749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Workshop plus Clinician-Collected Cervical Swab
Description: clinician-collection methods using speculum and cervical swabs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Workshop plus Participant-Collected Cervical Swab
Description: Evalyn® Brush (Rovers® Medical Devices, Netherlands)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing on Participant-Collected Cervical Swab Samples
Description: Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
Study: NCT04942834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone
Description: Class I or III antiarrhythmic drug, including sotalol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
Study: NCT04951947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS201 combine with Lenvatinib
Description: JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
Study: NCT04336553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social prescribing in Sweden (SPiS)
Description: Social prescribing in sweden (SPiS)
Study: NCT05987930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone lid technique
Description: group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard technique
Description: group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
Study: NCT05447780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
Study: NCT04664686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF catheter ablation
Description: Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: AV node ablation
Study: NCT06128954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 900mg TETA 4HCl Once Daily Formulation
Description: 3x300mg trientine base tablets as a single AM dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 900mg TETA 4HCl Cuprior®
Description: 6 x150mg trientine base tablets in two equally divided doses
Study: NCT06207591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG (electrocorticography) sensing
Description: Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
Study: NCT04590521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil®, Merck
Description: Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
Study: NCT05199077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-XANTHO
Description: a topical applied ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-XANTHO
Description: a topical applied ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GM-XANTHO
Description: a topical applied ointment
Study: NCT05128916

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intralesional platelet rich plasma
Description: Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intralesional platelet rich plasma
Description: Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral terbinafine
Description: Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral terbinafine
Description: Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
Study: NCT05142137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinkable solution
Description: The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinkable solution
Description: The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinkable solution
Description: The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
Study: NCT06375967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm.
Study: NCT06185543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC
Description: Ciprofloxacin and celecoxib combination extended release formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matches active drug in size, color and taste
Study: NCT06474611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nudge
Description: Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nudge
Description: Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
Study: NCT04762589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
Study: NCT05401279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four to six 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70mg\^m2 will be administered on Day 1 for four to six 21-day cycles.
Study: NCT04876742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beer
Description: As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
Study: NCT05271292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles
Study: NCT05469399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment).
Study: NCT05030545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.